AbCellera Biologics Inc 8-K, filed Mar 13, 2023
AbCellera Biologics Inc. (ABCL)
About this 8-K
AbCellera Biologics Inc filed this 8-K on March 13, 2023, reporting on events of March 10, 2023.
Items reported
- Item 7.01: Regulation FD disclosure
|
|
|
|
|
|
||
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
__________________________________________________
FORM
__________________________________________________
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
__________________________________________________
(Exact name of registrant as specified in its charter)
__________________________________________________
|
|
|
|
|
Not Applicable |
|
(State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification Number) |
|
|
|
|
|
|
|
(Address of registrant’s principal executive office) |
|
|
|
(Zip code) |
(
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
__________________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class |
Trading symbol(s) |
Name of each exchange on which registered |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|
|
|
|
|
|
||
Item 7.01 Regulation FD Disclosure
AbCellera Biologics Inc. (“The Company”) currently maintains a nominal amount of cash (<$15,000 USD) with Silicon Valley Bank (“SVB”) to secure a corporate credit card. The Company informs its investors that it does not hold any other cash deposits or securities at SVB and has no material exposure because of its relationship with SVB.
The information in Item 7.01 of this Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section. The information in this Item 7.01 shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Forward-Looking Statements
The Company cautions you that statements included in this report that are not a description of historical facts are forward-looking statements. These forward-looking statements include statements regarding any liquidity concern. The inclusion of forward-looking statements should not be regarded as a representation by the Company that any of these results will be achieved. Actual results may differ from those set forth in this report due to the risks and uncertainties associated with liquidity concerns, as well as risks and uncertainties inherent in the Company’s business, including those described in the Company’s other filings with the Securities Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and the Company undertakes no obligation to revise or update this report to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Date: March 10, 2023 |
ABCELLERA BIOLOGICS INC. |
||||||||||
|
|
|
|
|||||||||
|
|
By: |
|
/s/ Carl L. G. Hansen |
||||||||
|
|
|
|
Carl L. G. Hansen, Ph.D. |
||||||||
|
|
|
|
Chief Executive Officer and Director (Principal Executive Officer) |
||||||||